Skip to content

The Vanderbilt Atrial Fibrillation Ablation Registry

The Vanderbilt Atrial Fibrillation Ablation Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02404415
Acronym
VAFAR
Enrollment
2478
Registered
2015-03-31
Start date
2011-10-01
Completion date
2028-10-01
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

catheter ablation, genomics

Brief summary

The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis.

Detailed description

The study population consists of patients at least 18 years of age who are scheduled for AF ablation at Vanderbilt University. Data recorded at enrollment includes a detailed past medical history and measurements from pre-ablation imaging (cardiac MRI or CT). At the time of ablation, a blood sample is collected for storage of plasma/serum and extraction of DNA, and details of the ablation procedure are recorded. Post-ablation monitoring for arrhythmia recurrence is performed according to a standard clinical follow-up schedule at 3, 6, and 12-months. ECG's are performed at each follow-up visit along with placement of an ambulatory ECG-monitor. At 6-months post-ablation, cardiac imaging with a repeat cardiac MRI or CT is performed.

Interventions

None listed

Sponsors

Vanderbilt University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \>18 years 2. Able to give written, informed consent 3. Scheduled for an ablation procedure to treat atrial fibrillation

Exclusion criteria

1\. None

Design outcomes

Primary

MeasureTime frame
Atrial fibrillation recurrence2 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMoore B Shoemaker, MD, MSCI

Vanderbilt University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026